Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CHRS

Coherus BioSciences (CHRS)

Coherus BioSciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CHRS
DateTimeSourceHeadlineSymbolCompany
14/05/202406:35Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CHRSCoherus BioSciences Inc
10/05/202406:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CHRSCoherus BioSciences Inc
10/05/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
10/05/202406:01GlobeNewswire Inc.Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CHRSCoherus BioSciences Inc
09/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
09/05/202421:30GlobeNewswire Inc.Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term LoanNASDAQ:CHRSCoherus BioSciences Inc
08/05/202423:00GlobeNewswire Inc.Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian CancerNASDAQ:CHRSCoherus BioSciences Inc
02/05/202406:30GlobeNewswire Inc.Coherus to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:CHRSCoherus BioSciences Inc
25/04/202400:02GlobeNewswire Inc.Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CHRSCoherus BioSciences Inc
08/04/202422:30GlobeNewswire Inc.Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual MeetingNASDAQ:CHRSCoherus BioSciences Inc
14/03/202407:01GlobeNewswire Inc.Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateNASDAQ:CHRSCoherus BioSciences Inc
06/03/202408:01GlobeNewswire Inc.Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024NASDAQ:CHRSCoherus BioSciences Inc
04/03/202422:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
04/03/202417:00GlobeNewswire Inc.Coherus Completes Divestiture of Ophthalmology FranchiseNASDAQ:CHRSCoherus BioSciences Inc
24/02/202409:33GlobeNewswire Inc.Coherus BioSciences Announces New Employment Inducement GrantsNASDAQ:CHRSCoherus BioSciences Inc
23/02/202409:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
23/02/202409:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
23/02/202408:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
22/02/202400:30GlobeNewswire Inc.Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvNASDAQ:CHRSCoherus BioSciences Inc
06/02/202400:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
06/02/202400:00GlobeNewswire Inc.Coherus Amends Term Loan Agreement with Pharmakon Advisors, LPNASDAQ:CHRSCoherus BioSciences Inc
24/01/202412:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
24/01/202412:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
23/01/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
22/01/202417:59Dow Jones NewsSandoz to Acquire Cimerli Business from Coherus for $170 MillionNASDAQ:CHRSCoherus BioSciences Inc
22/01/202417:15GlobeNewswire Inc.Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash DealNASDAQ:CHRSCoherus BioSciences Inc
19/01/202408:05GlobeNewswire Inc.Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers SymposiumNASDAQ:CHRSCoherus BioSciences Inc
10/01/202413:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
10/01/202413:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
10/01/202411:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
 Showing the most relevant articles for your search:NASDAQ:CHRS